214 related articles for article (PubMed ID: 28052520)
1. IKAROS expression in distinct bone marrow cell populations as a candidate biomarker for outcome with lenalidomide-dexamethasone therapy in multiple myeloma.
Bolomsky A; Hübl W; Spada S; Müldür E; Schlangen K; Heintel D; Rocci A; Weißmann A; Fritz V; Willheim M; Zojer N; Palumbo A; Ludwig H
Am J Hematol; 2017 Mar; 92(3):269-278. PubMed ID: 28052520
[TBL] [Abstract][Full Text] [Related]
2. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K; Fibiger Munch-Petersen H; Winther Eskelund C; Dissing Sjö L; Ralfkiaer E; Gimsing P; Grønbaek K
Leuk Lymphoma; 2019 Jan; 60(1):180-188. PubMed ID: 29718735
[TBL] [Abstract][Full Text] [Related]
3. Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma.
Zhu YX; Braggio E; Shi CX; Kortuem KM; Bruins LA; Schmidt JE; Chang XB; Langlais P; Luo M; Jedlowski P; LaPlant B; Laumann K; Fonseca R; Bergsagel PL; Mikhael J; Lacy M; Champion MD; Stewart AK
Blood; 2014 Jul; 124(4):536-45. PubMed ID: 24914135
[TBL] [Abstract][Full Text] [Related]
4. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
5. IKZF1 expression is a prognostic marker in newly diagnosed standard-risk multiple myeloma treated with lenalidomide and intensive chemotherapy: a study of the German Myeloma Study Group (DSMM).
Krönke J; Kuchenbauer F; Kull M; Teleanu V; Bullinger L; Bunjes D; Greiner A; Kolmus S; Köpff S; Schreder M; Mügge LO; Straka C; Engelhardt M; Döhner H; Einsele H; Bassermann F; Bargou R; Knop S; Langer C
Leukemia; 2017 Jun; 31(6):1363-1367. PubMed ID: 28017969
[TBL] [Abstract][Full Text] [Related]
6. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in
Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF
Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557
[TBL] [Abstract][Full Text] [Related]
7. High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide.
Pourabdollah M; Bahmanyar M; Atenafu EG; Reece D; Hou J; Chang H
J Hematol Oncol; 2016 Nov; 9(1):123. PubMed ID: 27881177
[TBL] [Abstract][Full Text] [Related]
8. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
9. The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages.
Mougiakakos D; Bach C; Böttcher M; Beier F; Röhner L; Stoll A; Rehli M; Gebhard C; Lischer C; Eberhardt M; Vera J; Büttner-Herold M; Bitterer K; Balzer H; Leffler M; Jitschin S; Hundemer M; Awwad MHS; Busch M; Stenger S; Völkl S; Schütz C; Krönke J; Mackensen A; Bruns H
Cancer Immunol Res; 2021 Mar; 9(3):265-278. PubMed ID: 33563611
[TBL] [Abstract][Full Text] [Related]
10. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
11. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
[TBL] [Abstract][Full Text] [Related]
12. Do baseline Cereblon gene expression and IL-6 receptor expression determine the response to thalidomide-dexamethasone treatment in multiple myeloma patients?
Bedewy AM; El-Maghraby SM
Eur J Haematol; 2014 Jan; 92(1):13-8. PubMed ID: 24118365
[TBL] [Abstract][Full Text] [Related]
13. The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma.
Fionda C; Abruzzese MP; Zingoni A; Cecere F; Vulpis E; Peruzzi G; Soriani A; Molfetta R; Paolini R; Ricciardi MR; Petrucci MT; Santoni A; Cippitelli M
Oncotarget; 2015 Sep; 6(27):23609-30. PubMed ID: 26269456
[TBL] [Abstract][Full Text] [Related]
14. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
15. Expression, mutation, and methylation of cereblon-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.
Tachita T; Kinoshita S; Ri M; Aoki S; Asano A; Kanamori T; Yoshida T; Totani H; Ito A; Kusumoto S; Komatsu H; Yamagata K; Kubo K; Tohkin M; Fukuda S; Iida S
Cancer Sci; 2020 Apr; 111(4):1333-1343. PubMed ID: 32061138
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.
Madan S; Lacy MQ; Dispenzieri A; Gertz MA; Buadi F; Hayman SR; Detweiler-Short K; Dingli D; Zeldenrust S; Lust J; Greipp PR; Rajkumar SV; Kumar S
Blood; 2011 Aug; 118(7):1763-5. PubMed ID: 21673347
[TBL] [Abstract][Full Text] [Related]
17. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone.
Heintel D; Rocci A; Ludwig H; Bolomsky A; Caltagirone S; Schreder M; Pfeifer S; Gisslinger H; Zojer N; Jäger U; Palumbo A
Br J Haematol; 2013 Jun; 161(5):695-700. PubMed ID: 23565715
[TBL] [Abstract][Full Text] [Related]
18. Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells.
Ishibashi M; Yamamoto J; Ito T; Handa H; Sunakawa-Kii M; Inokuchi K; Morita R; Tamura H
Mol Cancer Ther; 2021 Jul; 20(7):1283-1294. PubMed ID: 33879556
[TBL] [Abstract][Full Text] [Related]
19. Multiple myeloma cells' capacity to decompose H
Sebastian S; Zhu YX; Braggio E; Shi CX; Panchabhai SC; Van Wier SA; Ahmann GJ; Chesi M; Bergsagel PL; Stewart AK; Fonseca R
Blood; 2017 Feb; 129(8):991-1007. PubMed ID: 28028022
[TBL] [Abstract][Full Text] [Related]
20. Patients with multiple myeloma treated with thalidomide: evaluation of clinical parameters, cytokines,angiogenic markers, mast cells and marrow CD57+ cytotoxic T cells as predictors of outcome.
Mileshkin L; Honemann D; Gambell P; Trivett M; Hayakawa Y; Smyth M; Beshay V; Ritchie D; Simmons P; Milner AD; Zeldis JB; Prince HM
Haematologica; 2007 Aug; 92(8):1075-82. PubMed ID: 17640854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]